Immunotherapeutic strategies, especially those targeting the Galectin-9/Tim-3/Foxp3 interaction, may serve as the potential salvage treatments for recurrent NPC33 in recurrent NPC. Here, LGALS9 is linked to nasopharyngeal carcinoma.